Yahoo Web Search

  1. The 2 Best Alternative Marijuana Stocks to Buy Now

    InvestorPlace via Yahoo FinanceMar 05 11:00 AM

    Marijuana is a key, long-term investment trend. As more states legalize recreational marijuana, it’ll be right up there with other “sin industries.” For example, wine alone is a $60 billion ...

  2. Biogen to Acquire Gene-Therapy Company Nightstar for $800M

    Zacks via Yahoo FinanceMar 05 21:53 PM

    Biogen BIIB announced that it has entered into an agreement to acquire London based clinical-stage gene-therapy company, Nightstar Therapeutics NITE. Shares of Nightstar gained 66% on the news ...

  3. Over the past week, mergers and acquisitions have grabbed headlines in the biotech sector. Shares of Spark Therapeutics and Clementia soared on buyout offers from Roche and Ipsen. Spark, Clementia ...

  4. Bull of the Day: GW Pharmaceuticals (GWPH)

    Zacks via Yahoo FinanceMar 04 10:01 AM

    GW Pharmaceuticals (GWPH) just delivered initial-launch sales numbers for the first FDA-approved cannabis-derived drug, Epidiolex, which was created and tested starting four years ago for the ...

  5. Why Adamas Pharmaceuticals Shares Are Crashing Today

    Motley Fool via Yahoo FinanceMar 05 17:40 PM

    Shares of Adamas Pharmaceuticals (NASDAQ: ADMS) were crashing 29.6% lower as of 11:39 a.m. EST on Tuesday. The biopharmaceutical company reported its fourth-quarter and full-year 2018 results ...

  6. February 22, 2019 – Zacks Equity Research GW Pharmaceuticals GWPH as the Bull of the Day, Hasbro HAS as the Bear of the Day. In addition, Zacks Equity Research provides analysis on Salesforce ...

  7. Liz Weston: Money mistakes even smart people make

    Associated Press via Yahoo FinanceMar 04 12:47 PM

    One client who repeatedly refused to buy disability insurance later developed multiple sclerosis. A technology company engineer balked at her suggestion to sell some of his stock ...

  8. 3 Arguments For and Against Buying GW Pharmaceuticals

    Motley Fool via Yahoo FinanceFeb 27 13:21 PM

    To be clear, it had gained approval in the EU for Sativex, a cannabinoid-based medicine for the treatment of spasticity associated with multiple sclerosis, years earlier, but Sativex ...

  9. PDUFA dates are deadlines for the FDA to review new drugs. The FDA is normally given 10 months to review new drugs. If a drug is selected for priority review, the FDA is allotted six months to review the drug.

  10. Activist hedge fund Starboard Value LP followed Bristol-Myers Squibb Co's second-largest investor, Wellington Management, in opposing the drugmaker's $74 billion purchase of biotech Celgene ...